Erlotinib: A successful clinical case and some notes about hepatic toxicity [0.03%]
厄洛替尼：一例成功的临床案例及关于肝脏毒性的几点说明
Agostinho Costa
Agostinho Costa
A case of a woman with lung adenocarcinoma in which fifteen-month disease control was achieved with second-line erlotinib treatment is presented. Five months after treatment beginning, isolated grade 3 hyperbilirubinemia occurred and daily ...
Ana Ferreira Alves,Marco Liebermann
Ana Ferreira Alves
Erlotinib is a molecule that selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity. The authors present a case that exemplifies the use of erlotinib as second line therapy for non-small cell lung cancer (NSCL...
Erlotinib in second-line therapy for non-small cell lung cancer - A clinical case [0.03%]
厄洛替尼用于二线治疗非小细胞肺癌 – 一例临床病例报告
Alexandra Araújo,Marta Soares,Isabel Azevedo et al.
Alexandra Araújo et al.
the epidermal growth-factor receptor (EGFR) and its signaling pathway have become a major target for therapy of non-small cell lung cancer (NSCLC). After the BR.21 study showed its effectiveness and its tolerability in older patients, erlot...
Pemetrexed in second line treatment of non-small cell lung cancer - The portuguese experience [0.03%]
非小细胞肺癌二线治疗中的培美曲塞——葡萄牙的经验
A Araújo,F Barata,B Parente et al.
A Araújo et al.
Until 2004, docetaxel in monotherapy was the standard for second-line treatment of non-small cell lung cancer (NSCLC). Pemetrexed (P) has shown similar activity in this setting with a better adverse event profile. In Portugal, it was introd...
New directions in the second line treatment of non-small cell lung cancers and in the management of malignant pleural mesotheliomas [0.03%]
非小细胞肺癌二线治疗及恶性胸膜间皮瘤管理的新方向
Renato Sotto-Mayor
Renato Sotto-Mayor
Mesothelioma treatment [0.03%]
间皮瘤的治疗
Bárbara Parente
Bárbara Parente
Malignant mesothelioma (MM) is a locally aggressive advanced tumour, with bad prognosis and many times fatal, who have been growing in the last two decades with possibilities to be continue in all the world until 2020, showing use of pic as...
Lung cancer treatment - Biology based decision, from gene to histology [0.03%]
肺癌治疗-基于生物学的决策，从基因到组织学
Venceslau Pinto Hespanhol
Venceslau Pinto Hespanhol
Lung cancer is the main cause of cancer mortality in the whole world. Until now, scientific and technologic developments didn't reduce significantly the mortality rate. The research of new therapeutical strategies based on individual charac...
Fernando Barata
Fernando Barata
Non small cell lung cancer (NSCLC), which is the leading cause of cancer mortality, is accounts for 85% of all cases of lung cancer. The majority of NSCLC patients present with advanced, unresectable disease. In advanced disease, chemothera...
Smoking habits in sixth year medicine students and antismoking measures in Portugal [0.03%]
葡萄牙六年级医学生吸烟习惯和控烟措施
André Borges,Filipa Marque,José Lima et al.
André Borges et al.